PI3Kδ signaling appears active inside Sjögren’s salivary glands
A study in primary Sjögren’s syndrome points to the PI3Kδ pathway as a biologically relevant target rather than a theoretical one. In glandular tissue from patients, phosphorylated ribosomal protein S6 was detected as a downstream marker of pathway activation, and its distribution aligned with immune-cell aggregates inside affected salivary glands. The signal was not diffuse background noise; it tracked with the very compartments where lymphocytes and plasma cells accumulate and drive tissue injury.
That pattern matters because Sjögren’s syndrome is not only a disease of dry mouth and dry eyes. It is an immune-mediated disorder marked by exocrine gland infiltration, B-cell hyperactivation, autoantibody production, and progressive loss of glandular function. A pathway that regulates lymphocyte metabolism, survival, proliferation, apoptosis, and migration sits squarely inside that biology. PI3Kδ has already been exploited in B-cell malignancies, so the question here was whether the same axis could be redirected toward autoimmune gland disease.
Salivary gland tissue showed pathway activation where immune injury is concentrated
Target validation assays found significant expression of phosphorylated S6 in salivary glands from patients with Sjögren’s syndrome. This downstream readout matters because it offers a tissue-level snapshot of ongoing intracellular signaling rather than a generalized inflammatory impression. The strongest staining clustered with T-cell and B-cell markers inside the glandular aggregates, and it also appeared in CD138+ plasma cells infiltrating the tissue.
The localization is clinically persuasive. Plasma cells are the effector arm of sustained autoantibody production, while the B-cell compartment helps sustain ectopic lymphoid organization within inflamed glands. A pathway that is active in both the cellular infiltrate and the antibody-producing compartment suggests more than incidental activation. It points to a signal that may be helping maintain the inflammatory architecture itself.
Seletalisib reduced glandular infiltrates in a murine model of focal sialoadenitis
Investigators then moved into a murine model of focal sialoadenitis, a system designed to mimic some features of Sjögren’s syndrome. In that model, blockade of PI3Kδ activity with seletalisib, a PI3Kδ-selective inhibitor, reduced lymphocyte and plasma cell accumulation within the salivary glands. The effect appeared in both prophylactic and therapeutic regimens, meaning the inhibitor was associated with less infiltration whether given before disease expression or after disease was already established.
That split is biologically important. A prophylactic effect suggests interference with immune-cell recruitment or expansion during disease initiation. A therapeutic effect suggests the pathway remains relevant after inflammation is established, when tissue remodeling and ectopic immune structures are already underway. In other words, the target was not confined to a narrow early window.
Chemokines, cytokines, and saliva flow all shifted with pathway inhibition
The intervention also altered production of lymphoid chemokines and cytokines linked to ectopic lymphoneogenesis. Those mediators are central to the formation and maintenance of organized immune aggregates in non-lymphoid tissue, and their reduction fits with the observed decline in infiltrating immune cells. The pathway effect extended beyond histology and into a broader inflammatory program that helps sustain chronic glandular disease.
One result stands out because it reaches directly into bedside function: saliva flow improved, and autoantibody production was significantly affected. For patients, glandular dysfunction is not an abstract biomarker problem. It translates into swallowing difficulty, oral discomfort, dental complications, and persistent symptoms that current therapy often addresses imperfectly. Any intervention that can move both immune activity and exocrine output in the same direction deserves close scrutiny.
The functional signal also strengthens the mechanistic argument. If PI3Kδ inhibition dampens lymphoid chemokine production, reduces plasma cell and lymphocyte burden, and changes autoantibody output, then the observed improvement in salivary flow becomes easier to understand. The drug is not acting like a nonspecific anti-inflammatory agent. It is interfering with an immune circuit that appears to help organize and perpetuate the glandular lesion.
Why PI3Kδ is a plausible target in Sjögren’s disease biology
PI3Kδ sits inside a signaling family that helps shape how lymphocytes behave once they are activated. In B-cell–driven disease, that makes the pathway attractive for two reasons. First, it can influence survival and proliferation of the very cells that dominate the inflammatory infiltrate. Second, it can affect trafficking and migration, which are critical for the establishment of salivary gland aggregates and ectopic lymphoid-like structures.
Sjögren’s syndrome is especially suited to this kind of intervention because the disease is not driven by a single cytokine or a single autoantibody. It is a chronic immune network disorder in which glandular damage is maintained by cellular crosstalk, local chemokine gradients, and persistent adaptive immune activation. A target that reaches into those shared mechanisms has a stronger biological rationale than one aimed at a downstream symptom alone.
The translational signal is strong, but the work remains preclinical
These findings support the idea that PI3Kδ inhibition could become a therapeutic strategy in primary Sjögren’s syndrome. Still, the evidence here comes from tissue studies in patients and from a murine disease model. The human component demonstrates pathway activation in affected glands, while the animal work shows what happens when the pathway is blocked. What is not yet established is whether these tissue and functional effects will translate into durable clinical benefit in patients with established disease.
The most useful next step is not speculation about a cure, but a disciplined clinical program that tests whether a PI3Kδ-selective inhibitor can improve glandular function, reduce systemic immune activity, and do so with an acceptable safety profile in human Sjögren’s syndrome. The current data justify that question. They do not answer it yet.